JNJ vs MMSI
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JNJ presents a dichotomy between strong profitability and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 3/9. While the company maintains an impressive ROE of 35.03% and a consistent history of earnings beats, the current price of $237.96 trades at a significant premium to its Graham Number of $91.72. Growth remains robust on a YoY basis, but bearish insider sentiment and a very weak technical trend (10/100) suggest immediate headwinds. The stock is fundamentally sound in terms of earnings power but shows signs of operational inefficiency or declining quality in its deterministic health metrics.
MMSI presents a dichotomy between strong fundamental growth and poor market sentiment. While the Piotroski F-Score of 4/9 indicates stable but not strong financial health, the company boasts an exceptional track record of earnings beats over 25 quarters and strong YoY earnings growth of 38.8%. However, the stock is currently trading at $70.54, which is a premium to its Intrinsic Value ($62.83) and significantly above its Graham Number ($35.75). Bearish insider activity and a 0/100 technical trend offset the bullish analyst target of $101.18.
Compare Another Pair
Related Comparisons
JNJ vs MMSI: Head-to-Head Comparison
This page compares Johnson & Johnson (JNJ) and Merit Medical Systems, Inc. (MMSI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.